B cell Activation in Sjögren's Syndrome, Cutaneous Lupus Erythematodus and Systemic Sclerosis Tissues Analysis 2 - BASTA2

reumatologie0 个研究点目标入组 20 人开始时间: 待定最近更新: 2024年4月15日

适应症

试验速览

暂无简介。

•lnclusion criteria for Sjögren's syndrome (SSj) patients are: diagnosis of
•primary SS according to the European American consensus group criteria, grade 3
•or 4 Chisholm score in salivary gland biopsy and presence of antinuclear (ANA),
•anti-SSA and/or anti-SSB antibodies.
•Inclusion criteria for CLE patients are: diagnosis of subacute cutaneous lupus
•erythematosus (SCLE) or SLE with cutaneous lupus according to the Düsseldorf
•classification criteria . Presence of anti-nuclear (ANA), anti-SSA and/or
•anti-SSB antibodies. Active skin disease as assessed by the treating physician.
•lnclusion criteria for the SSc patients are: diagnosis of early diffuse
•cutaneous SSc, according to the VEDOSS criteria defined as having a diffuse
•skin involvement, presence of anti-nuclear antibodies (ANA) a disease duration
•(from fìrst non-ñaynaud symptom) of < 3 years and progressive disease as
•defined by an increase in mean Rodnan skin score (hnSS) > 10 points or > 25% in
•the past year. Patients will be selected with skin involvement of the legs,
•which allows the analysis of an inguinal lymph node as locoregional lymph node.

•Exclusion criteria for both SSj patients and SSc patients are presence of
•active concurrent inflammatory or infectious condition, current or previous use
•of biologic treatment, previous other systemic autoimmune disease, diagnosis or
•positive serology for hepatitis C or Human lmmunodeficiëncy Virus.

发起方

reumatologie